Rock Springs Capital Master Fund Lp - Net Worth and Insider Trading
Rock Springs Capital Master Fund Lp Net Worth
The estimated net worth of Rock Springs Capital Master Fund Lp is at least $27 Million dollars as of 2024-11-13. Rock Springs Capital Master Fund Lp is the 10% Owner of Inozyme Pharma Inc and owns about 2,111,768 shares of Inozyme Pharma Inc (INZY) stock worth over $8 Million. Rock Springs Capital Master Fund Lp is the 10% Owner of Verve Therapeutics Inc and owns about 1,079,224 shares of Verve Therapeutics Inc (VERV) stock worth over $7 Million. Rock Springs Capital Master Fund Lp is also the 10% Owner of Atea Pharmaceuticals Inc and owns about 1,944,419 shares of Atea Pharmaceuticals Inc (AVIR) stock worth over $6 Million. Besides these, Rock Springs Capital Master Fund Lp also holds Imara Inc (IMRA) , Theseus Pharmaceuticals Inc (THRX) , Homology Medicines Inc (FIXX) . Details can be seen in Rock Springs Capital Master Fund Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Rock Springs Capital Master Fund Lp has not made any transactions after 2021-10-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Rock Springs Capital Master Fund Lp
Rock Springs Capital Master Fund Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Rock Springs Capital Master Fund Lp owns 9 companies in total, including Inozyme Pharma Inc (INZY) , Imara Inc (IMRA) , and Homology Medicines Inc (FIXX) among others .
Insider Ownership Summary of Rock Springs Capital Master Fund Lp
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
INZY | Inozyme Pharma Inc | 2020-07-28 | 10 percent owner |
IMRA | Imara Inc | 2020-03-16 | 10 percent owner |
FIXX | Homology Medicines Inc | 2018-04-02 | 10 percent owner |
2021-12-30 | 10 percent owner | ||
2020-11-03 | 10 percent owner | ||
2021-10-12 | 10 percent owner | ||
2021-10-21 | 10 percent owner | ||
2021-06-21 | 10 percent owner | ||
2020-03-11 | 10 percent owner |
Rock Springs Capital Master Fund Lp Latest Holdings Summary
Rock Springs Capital Master Fund Lp currently owns a total of 6 stocks. Among these stocks, Rock Springs Capital Master Fund Lp owns 2,111,768 shares of Inozyme Pharma Inc (INZY) as of July 28, 2020, with a value of $8 Million and a weighting of 28.89%. Rock Springs Capital Master Fund Lp owns 1,079,224 shares of Verve Therapeutics Inc (VERV) as of June 21, 2021, with a value of $7 Million and a weighting of 25.25%. Rock Springs Capital Master Fund Lp also owns 1,944,419 shares of Atea Pharmaceuticals Inc (AVIR) as of November 3, 2020, with a value of $6 Million and a weighting of 23.56%. The other 3 stocks Imara Inc (IMRA) , Theseus Pharmaceuticals Inc (THRX) , Homology Medicines Inc (FIXX) have a combined weighting of 22.3% among all his current holdings.
Latest Holdings of Rock Springs Capital Master Fund Lp
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
INZY | Inozyme Pharma Inc | 2020-07-28 | 2,111,768 | 3.76 | 7,940,248 |
VERV | Verve Therapeutics Inc | 2021-06-21 | 1,079,224 | 6.43 | 6,939,410 |
AVIR | Atea Pharmaceuticals Inc | 2020-11-03 | 1,944,419 | 3.33 | 6,474,915 |
IMRA | Imara Inc | 2020-03-16 | 523,411 | 6.32 | 3,307,958 |
THRX | Theseus Pharmaceuticals Inc | 2021-10-12 | 686,649 | 4.06 | 2,787,795 |
FIXX | Homology Medicines Inc | 2018-04-02 | 35,880 | 0.93 | 33,537 |
Holding Weightings of Rock Springs Capital Master Fund Lp
Rock Springs Capital Master Fund Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Rock Springs Capital Master Fund Lp has made a total of 1 transactions in Inozyme Pharma Inc (INZY) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Inozyme Pharma Inc is the acquisition of 600,000 shares on July 28, 2020, which cost Rock Springs Capital Master Fund Lp around $10 Million.
According to the SEC Form 4 filings, Rock Springs Capital Master Fund Lp has made a total of 1 transactions in Verve Therapeutics Inc (VERV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Verve Therapeutics Inc is the acquisition of 370,000 shares on June 21, 2021, which cost Rock Springs Capital Master Fund Lp around $7 Million.
According to the SEC Form 4 filings, Rock Springs Capital Master Fund Lp has made a total of 1 transactions in Atea Pharmaceuticals Inc (AVIR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Atea Pharmaceuticals Inc is the acquisition of 250,000 shares on November 3, 2020, which cost Rock Springs Capital Master Fund Lp around $6 Million.
More details on Rock Springs Capital Master Fund Lp's insider transactions can be found in the Insider Trading History of Rock Springs Capital Master Fund Lp table.Insider Trading History of Rock Springs Capital Master Fund Lp
- 1
Rock Springs Capital Master Fund Lp Trading Performance
GuruFocus tracks the stock performance after each of Rock Springs Capital Master Fund Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Rock Springs Capital Master Fund Lp is 66.75%. GuruFocus also compares Rock Springs Capital Master Fund Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Rock Springs Capital Master Fund Lp within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Rock Springs Capital Master Fund Lp's insider trading performs compared to the benchmark.
Performance of Rock Springs Capital Master Fund Lp
Rock Springs Capital Master Fund Lp Ownership Network
Ownership Network List of Rock Springs Capital Master Fund Lp
Ownership Network Relation of Rock Springs Capital Master Fund Lp
Rock Springs Capital Master Fund Lp Owned Company Details
What does Inozyme Pharma Inc do?
Who are the key executives at Inozyme Pharma Inc?
Rock Springs Capital Master Fund Lp is the 10 percent owner of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and See Remarks Henric Bjorn Bjarke .
Inozyme Pharma Inc (INZY) Insider Trades Summary
Over the past 18 months, Rock Springs Capital Master Fund Lp made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , a net purchase of 833,333 shares made by Robert Lorne Hopfner , and a net sale of 7,523 shares made by Douglas A Treco .
In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 1,666,666 shares were bought by its insiders, resulting in a net purchase of 1,659,143 shares.
Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inozyme Pharma Inc Insider Transactions
Rock Springs Capital Master Fund Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Rock Springs Capital Master Fund Lp. You might contact Rock Springs Capital Master Fund Lp via mailing address: 190 Elgin Avenue, George Town E9 Ky1 9001.